Company intelligence / Profile preview

Onyvax

London, West Yorkshire, United Kingdomuk.linkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed enrollment for Phase IIb clinical trial for Onyvax-P (prostate cancer vaccine) in 2008. Previous Phase IIa data showed significant slowing of PSA rise in 40% of patients and extended time to disease progression to 58 weeks compared to historical experience of 29-30 weeks[5]. Also identified a biomarker profile that could predict patient response to cancer vaccine therapy[3].

Therapeutic areas: Oncology
Modalities: Cancer vaccinesImmunotherapy
Industry: Biotech

Drug pipeline

5 assets

Prostate cancer vaccine ONY-P1

4 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with John van Geest Cancer Research Centre at Nottingham Trent University[3]

Beyond the preview

Go deeper on Onyvax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onyvax.

Explore the full profile